{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:54:15Z","timestamp":1790013255713,"version":"4.0.1"},"reference-count":58,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T00:00:00Z","timestamp":1244419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Rosacea is a common, often overlooked, chronic facial dermatosis characterized by intermittent periods of exacerbation and remission. Clinical subtypes and grading of the disease have been defined in the literature. On the basis of a genetic predisposition, there are several intrinsic and extrinsic factors possibly correlating with the phenotypic expression of the disease. Although rosacea cannot be cured, there are several recommended treatment strategies appropriate to control the corresponding symptoms\/signs. In addition to adequate skin care, these include topical and systemic medications particularly suitable for the papulopustular subtype of rosacea with moderate to severe intensity. The most commonly used and most established therapeutic regimens are topical metronidazole and topical azelaic\u00a0acid as well as oral doxycycline. Conventionally, 100\u2013200\u00a0mg per day have been used. Today also a controlled release formulation is available, delivering 40\u00a0mg per day using non\u2010antibiotic, anti\u2010inflammatory activities of the drug. Anti\u2010inflammatory dose doxycycline in particular allows for a safe and effective short\u2010 and long\u2010term therapy of rosacea. Topical metronidazole and topical azelaic\u00a0acid also appear to be safe and effective for short\u2010term use. There are indications that a combined therapy of anti\u2010inflammatory dose doxycycline and topical metronidazole could possibly have synergy effects. Further interesting therapy options for the short\u2010 and long\u2010term therapy of rosacea could be low\u2010dose minocycline and isotretinoin; however, too little data are available with regard to the effectiveness, safety, optimal dosage and appropriate length of treatment for these medications to draw final conclusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conflicts of interest<\/jats:title>\n                    <jats:p>None declared.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1468-3083.2009.03167.x","type":"journal-article","created":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T04:14:43Z","timestamp":1244434483000},"page":"876-882","source":"Crossref","is-referenced-by-count":71,"title":["Current topical and systemic approaches to treatment of rosacea"],"prefix":"10.1111","volume":"23","author":[{"given":"HC","family":"Korting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sch\u00f6llmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,6]]},"reference":[{"key":"e_1_2_19_2_2","first-page":"435","article-title":"Rosacea: a common yet commonly overlooked condition","volume":"66","author":"Blount BW","year":"2002","journal-title":"Am Fam Physician"},{"key":"e_1_2_19_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-006-0062-z"},{"key":"e_1_2_19_4_2","first-page":"419","article-title":"An epidemiological study of rosacea","volume":"69","author":"Berg M","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_19_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000077298"},{"key":"e_1_2_19_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.05.018"},{"key":"e_1_2_19_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_2_19_8_2","first-page":"156","article-title":"Women commonly seek care for rosacea: dermatologists frequently provide the care","volume":"68","author":"Feldman SR","year":"2001","journal-title":"Cutis"},{"key":"e_1_2_19_9_2","first-page":"1","article-title":"Facial skin complaints and work at visual display units. Epidemiological, clinical and histopathological studies","volume":"150","author":"Berg M.","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_19_10_2","unstructured":"GuttmanC.Rosacea prevalence underestimated [WWW document]2006. URL:http:\/\/www.modernmedicine.com\/modernmedicine\/ClinicalDermatology\/Rosacea\u2010prevalence\u2010underestimated\/ArticleStandardArticle\/detail\/383156(last accessed 23 May 2009)."},{"key":"e_1_2_19_11_2","first-page":"1","article-title":"Systemic therapy for rosacea","volume":"12","author":"Baldwin HE","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_19_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2003.01876.x"},{"key":"e_1_2_19_13_2","unstructured":"BikowskiJ.Examining inflammation as a common factor in theories of rosacea pathophysiology [WWW document] 2008. URLhttp:\/\/www.rosaceatoday.com\/TheoriesofRosacea.asp(last accessed 5\u00a0May 2009)."},{"key":"e_1_2_19_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.033"},{"key":"e_1_2_19_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_19_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_19_17_2","first-page":"254","article-title":"Treatment of rosacea with intense pulsed light","volume":"2","author":"Taub AF","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_18_2","first-page":"35","article-title":"Laser and light therapies for acne rosacea","volume":"5","author":"Butterwick KJ","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.7.884"},{"key":"e_1_2_19_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.069"},{"key":"e_1_2_19_21_2","first-page":"641","article-title":"Combined effect of anti\u2010inflammatory dose doxycycline (40\u2010mg doxycycline, usp monohydrate controlled\u2010release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler JF","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb03993.x"},{"key":"e_1_2_19_23_2","first-page":"73","article-title":"The CLEAR trial: results of a large community\u2010based study of metronidazole gel in rosacea","volume":"79","author":"Wolf JE","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_19_24_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.116219"},{"key":"e_1_2_19_25_2","first-page":"317","article-title":"Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter?","volume":"5","author":"Yoo Y","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.084"},{"key":"e_1_2_19_27_2","first-page":"12","article-title":"A look at the safety of metronidazole 1% gel: cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential","volume":"77","author":"Beutner KR","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_19_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70085-X"},{"key":"e_1_2_19_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1444"},{"key":"e_1_2_19_30_2","first-page":"3","article-title":"Efficacy and safety of once\u2010daily metronidazole 1% gel compared with twice\u2010daily azalaic acid 15% gel in the treatment of rosacea","volume":"77","author":"Wolf JE","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_19_31_2","first-page":"209","article-title":"Topical metronidazole in the treatment of rosacea","volume":"38","author":"Veien NK","year":"1986","journal-title":"Cutis"},{"key":"e_1_2_19_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2004.tb00566.x"},{"key":"e_1_2_19_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_2_19_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639709160276"},{"key":"e_1_2_19_35_2","first-page":"271","article-title":"A status report on the medical management of rosacea: focus on topical therapies","volume":"70","author":"Del Rosso JQ","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_19_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141050-00007"},{"key":"e_1_2_19_37_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_19_38_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639309082150"},{"key":"e_1_2_19_39_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2005.04045"},{"key":"e_1_2_19_40_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114739"},{"key":"e_1_2_19_41_2","doi-asserted-by":"publisher","DOI":"10.1053\/sder.2001.29061"},{"key":"e_1_2_19_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639309084517"},{"key":"e_1_2_19_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70147-L"},{"key":"e_1_2_19_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051380"},{"key":"e_1_2_19_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1966.tb12168.x"},{"key":"e_1_2_19_46_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.1.5"},{"key":"e_1_2_19_47_2","first-page":"251","article-title":"Rosacea: where are we now?","volume":"3","author":"Bikowski JB","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.004"},{"key":"e_1_2_19_49_2","first-page":"411","article-title":"Second generation tetracyclines, a dermatological overview: clinical uses and pharmacology","volume":"48","author":"Maibach H.","year":"1991","journal-title":"Cutis"},{"key":"e_1_2_19_50_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.1.1025697"},{"key":"e_1_2_19_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2007.06460.x"},{"key":"e_1_2_19_52_2","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2007.070015"},{"key":"e_1_2_19_53_2","first-page":"343","article-title":"Clarithromycin: a new perspective in rosacea treatment","volume":"37","author":"Torresani C.","year":"1998","journal-title":"Int J Dermatol"},{"key":"e_1_2_19_54_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00301.x"},{"key":"e_1_2_19_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.01958.x"},{"key":"e_1_2_19_56_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690030051008"},{"key":"e_1_2_19_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92160-7"},{"key":"e_1_2_19_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb06558.x"},{"key":"e_1_2_19_59_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.38.9.1076-b"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03167.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03167.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:01:07Z","timestamp":1697047267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03167.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,6]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03167.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03167.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,6]]}}}